NIH Shopping Peptide Eyedrops to Save Your Vision
Published Date: 7/24/2026
Notice
Summary
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Potential New Treatment for Retinal Degeneration
Researchers developed a 17-amino-acid PEDF peptide (17-mer [H105A]) that showed potent protective effects on photoreceptors in in vivo mouse models. This peptide could be developed as an eyedrop or AAV2 gene-delivery therapy to prevent or slow photoreceptor degeneration in inherited retinal diseases like retinitis pigmentosa (affecting over 100,000 people in the U.S.) and in age-related macular degeneration.
NIH Offering PEDF Licensing Opportunity
The National Eye Institute (NEI) is seeking partners or licensees to co-develop a Pigment Epithelium-Derived Factor (PEDF) peptide therapy using either an AAV2-based delivery system or an eyedrop formulation. The technology is offered with NIH Reference Number E-028-2023 and is available for licensing and co-development now.
Therapy Still at Pre-Clinical Stage
The PEDF peptide technology and delivery approaches are at the pre-clinical development stage (in vivo validation). That means the therapy is not yet approved or available for clinical use while further development is pursued.
Developer Advantage: AAV2 Pathway Similarity
NEI notes the AAV2 vector approach is identical to Luxturna, an FDA-approved retinal therapy, suggesting a partially established regulatory path for developers pursuing an AAV2 delivery route. The notice highlights competitive advantages such as favorable safety profile and lower production costs compared with biologics.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
2026-14848, Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
The National Institutes of Health plans to give Modala Bio an exclusive license to use new RXFP1 agonist inventions that could help treat diseases like cancer, heart failure, and fibrosis. This means Modala Bio gets special rights to develop and sell these promising medicines worldwide. If you want to comment or apply for a license, you have until August 24, 2026, so don’t miss out!
2026-14752, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in August 2026 to review and evaluate important grant and contract proposals. These meetings protect private info and trade secrets while deciding who gets funding to fight antibiotic resistance, support schizophrenia research, and boost medical tech. If you’re involved in these fields, keep an eye on these dates—they could impact future research dollars and projects.
2026-14666, National Institute of Neurological Disorders and Stroke; Notice of Meeting
The National Institute of Neurological Disorders and Stroke is hosting a free, virtual meeting on August 24, 2026, to talk about Parkinson’s disease research, care, and services. This meeting affects people with Parkinson’s, their families, and organizations working on the disease, as it will share updates and plan a federal list of Parkinson’s programs. Public comments are welcome until August 10, giving everyone a chance to join the conversation and help shape future efforts.
Previous / Next Documents
Previous: 2026-14979, Cboe Clear U.S., LLC; Notice of Filing of an Application, as Amended, for Temporary Registration as a Clearing Agency Under Section 17A of the Securities Exchange Act of 1934
Cboe Clear U.S., LLC wants to become a temporary official clearing agency to handle special financial contracts called binary options. This change affects traders and companies dealing with these contracts by adding a trusted middleman to make sure trades settle smoothly. The SEC is reviewing the application and asking for public feedback before making a final decision.
Next: 2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.